Also called: GLP-1 + AOD-9604, GLP-1 peptide, GLP-1 with Vitamin B12/B6
GLP-1 is a small protein made in the body that helps control how much food you eat. It works like a message sent from the gut to the brain to tell you that you are full. Doctors look at this substance to help people with health problems related to sugar and weight. It is often grouped with other body signals like leptin and insulin that manage hunger and energy.
The main job of GLP-1 is to slow down how fast food leaves the stomach and to tell the pancreas to release insulin. This helps lower the amount of sugar in the blood after a meal. Because it makes you feel full, it is used to help people eat less and manage their weight better. It works closely with other hormones to keep the body's energy in balance.
Scientists are still studying the best ways to use this substance for different health needs. While it is helpful for blood sugar and weight, researchers are still learning about all its effects on the body. There is also a lot of focus on how to make and measure this protein correctly in labs. It is important to follow medical advice when using treatments that affect hunger hormones.
Benefits
The main themes across 304 research studies, in plain language.
Research suggests these mechanisms help stabilize blood sugar levels by enhancing insulin secretion and sensitivity in response to glucose.
Research focuses on extending the stability and half-life of therapeutic peptides for improved delivery.
Laboratory studies suggest these compounds may help preserve insulin-producing cells in the pancreas and reduce cellular stress.
Evidence suggests potential benefits for brain health, including protection against inflammation, plaque buildup, and cognitive decline.
Preliminary research suggests potential to dampen brain reward pathways associated with cravings for substances like nicotine and alcohol.
Evidence points to potential benefits for liver metabolism, including the reduction of fat accumulation and improved lipid profiles.
Studies indicate potential to support kidney health and reduce the risk of disease progression.
Research suggests potential roles in supporting bone density, joint health, and muscle function.
Research suggests a role in slowing the emptying of the stomach and regulating gut movement.
Research indicates the ability to lower inflammatory markers and modulate immune responses in various tissues.
Studies suggest mechanisms that protect cells from stress, damage, and programmed cell death.
Studies indicate effects on reducing appetite, slowing digestion, and decreasing food intake to support weight loss.
Research points to protective effects on the heart and blood vessels, including improved function and reduced risk of major adverse events.
Emerging clinical evidence is exploring potential benefits for conditions like obstructive sleep apnea.
You just read the research on GLP-1. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Honest expectations
What the sourced research says it doesn’t do — as notable as what it does.
Safety
Adverse effects reported in the research and by community use.
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Timeline
Key moments in GLP-1’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions GLP-1.
This journal listing includes several articles touching on obesity pharmacotherapy, most notably a systematic review and meta-analysis of subcutaneous semaglutide's effects on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Additional items examine GLP-1 receptor agonists from a rheumatological perspective and self-medication with GLP-1 drugs among Brazilian adults. The listing also covers broader obesity research, including bariatric surgery positioning and epidemiological studies.
New research suggests that semaglutide reduces the risk of major adverse cardiovascular events (MACE) not only through weight loss but also by lowering systemic inflammation. A study of over 17,000 patients found that reductions in the inflammatory biomarker hs-CRP accounted for roughly 28% of the drug's cardiovascular benefit. This indicates that semaglutide's mechanism for heart protection involves direct anti-inflammatory effects independent of glycemic control or body weight reduction.
An analysis of rate filings from small group insurers indicates that small businesses may face a median premium increase of 14% in 2027. The filings identify rising healthcare costs and increased utilization as primary factors, specifically highlighting the financial impact of specialty drugs. Insurers explicitly cite GLP-1 medications as a significant driver behind these escalating costs and subsequent premium hikes.
Novo Nordisk's U.S. news portal highlights several key developments regarding its peptide-based portfolio. The company is actively challenging Eli Lilly's advertising campaigns regarding GLP-1 therapies, signaling ongoing market competition. Additionally, Novo Nordisk reported positive Phase 3 results for its hemophilia A drug denecimig and expanded access to Wegovy for Medicare beneficiaries.
Novo Nordisk has announced two major regulatory milestones in the European Union. The company received approval for an oral version of its weight management drug Wegovy, as well as a new 7.2 mg dose pen. Additionally, the company is taking legal action against Eli Lilly regarding misleading GLP-1 advertising campaigns.
Wondering how GLP-1 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.